Canaccord Maintains Buy, $70 Tgt On Atara Biotherapeutics Ahead Of 'preliminary efficacy data at ECTRIMS on Friday, 9/13, in n=12 patients at 6 months of follow-up and will discuss changes in EDSS score, a key endpoint for progressive multiple sclerosis'
Benzinga_Newsdesk